Fig. 3.

Effect of different drug delivery strategies on the biodistribution of EVs

(A)Biodistribution of EVs by different injection methods. i. v.: Intravenous injection; i. p.: Intraperitoneal Injections; s. c.: Subcutaneous Injections. Adapted reprinted with permission from Ref. [74], based on Creative Commons Attribution-NonCommercial 4.0 International Public License (CC BY-NC 4.0) © 2015 Oscar P. B. Wiklander et al. (B) Biodistribution of EVs for inhalation drug delivery, EVs were observed in the lungs only during a period of up to seven days. Adapted reprinted with permission from Ref. [76], Copyright @ 2022 Elsevier B.V. All rights reserved. (License number: 5,440,810,081,513). (C) Biodistribution of topically administered EVs. Adapted reprinted from with permission [77], Copyright @ 2022 The Authors, Small published by Wiley-VCH GmbH (License number:5,440,810,773,416).